Drug profile · INN
efgartigimod alfa
VYVGART
efgartigimod alfa (VYVGART) is a igg receptor fcrn large subunit p51 antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — efgartigimod alfa
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 12
- Data quality
- 0.84
Quick answer
efgartigimod alfa (VYVGART) is a igg receptor fcrn large subunit p51 antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
IgG receptor FcRn large subunit p51 antagonist
Primary target: IgG receptor FcRn large subunit p51
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is efgartigimod alfa?
efgartigimod alfa (VYVGART) is a igg receptor fcrn large subunit p51 antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for efgartigimod alfa?
VYVGART is a marketed brand name for efgartigimod alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of efgartigimod alfa?
efgartigimod alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.